Revolutionizing cancer monitoring

Personalized cancer monitoring with remarkable sensitivity from a simple blood sample

Because cancer is personal

Cancer affects everyone, from the patient to their loved ones. Each patient has a unique story, and every cancer is also different. Despite that each tumor possesses its own set of DNA mutations, patients often undergo testing and treatment using the same standardized and inflexible methods.

More personal is more sensitive

Given the uniqueness of each tumor, a uniform testing approach may not be sensitive enough to detect cancer. For that reason we developed Simsen® Personal a customized cancer DNA test for each patient, offering next level sensitivity and specificity for monitoring cancer.

Make cancer curable with ultrasensitive monitoring

Simsen Diagnostics is a Swedish biotech company that specializes in ultrasensitive technologies for cancer monitoring. Founded in 2020,
our mission is to make cancer a curable disease.

We envision a future where ultrasensitive analysis can revolutionize healthcare and contribute to faster, accurate, and more sensitive diagnoses of a wide range of diseases.


Pontus Rehn

Chief Executive Officer (CEO)

Pontus Rehn has over 20 years of experience in commercial leadership roles in the medical device and IVD industries, including global and regional positions like VP Market Development, Chief Commercial Officer, and Director of Commercial Strategy. 

Lina Said

Laboratory and Quality Manager

Lina Said, a licensed Biomedical Scientist, brings 18 years of experience from Sahlgrenska University Hospital to her role as the Lab and Quality Manager at Simsen Diagnostics. Her primary focus is ensuring quality assurance and fostering an optimal work environment for the lab. 

My Vu

Lead Laboratory Technician

My Vu is currently doing a master’s degree in biotechnology and demonstrates expertise in laboratory procedures. Her previous experience includes analyzing COVID samples and conducting her bachelor’s thesis at Fraunhofer. My is analyzing all the samples that comes to the lab.  

Stefan Filges

Chief Technology Officer (CTO)

Stefan Filges, an accomplished bioinformatician with a Ph.D. in ultrasensitive sequencing, became part of Simsen Diagnostics in 2022. He played a crucial role as a co-author in the original publication of SiMSen-Seq, which was published in Nature Protocols. 

Camilla Hietanen

Head of Sales and Marketing

Camilla Hietanen holds an M.Sc. in Business Development from the Chalmers School of Entrepreneurship. Her academic background encompasses studies in Sports & Nutrition, and she brings prior experience from various Start-ups. Within Simsen Diagnostics, her primary focus lies in Sales and Marketing. 

Almost there

Sign up on our maillist to gain access to your article. You can at any time unsubscribe from the list.